Key result
The CHA2DS2-VASc score significantly predicted 3- to 5-year all-cause mortality in patients with atrial fibrillation, with each 1-point increase raising the odds of death (OR 1.71).
Why the study?
Patients with AF face an increased risk of fatal complications such as stroke, motivating investigation into the predictive value of CHA2DS2-VASc scores for stroke and all-cause mortality.
Does the CHA2DS2-VASc score predict stroke and all-cause mortality in patients with atrial fibrillation?
Cohort (n=137)
No
Does the CHA2DS2-VASc score predict stroke and all-cause mortality in patients with atrial fibrillation?
The CHA2DS2-VASc score is a significant predictor of 3 to 5-year mortality and stroke incidence in patients with atrial fibrillation.
May support CHA2DS2-VASc for AF mortality prognostication; leaves open prospective validation and intervention trials.
BACKGROUND: Patients with atrial fibrillation (AF) have a higher risk of fatal complications (e.g., stroke). This investigation was performed as an observational retrospective cohort study includes 137 patients (age 61 ± 15; 34.3% women) with a primary diagnosis of AF (paroxysmal, persistent, and permanent). METHODS: We collected information about the drug therapy, comorbidities and survival of AF patients and determined their congestive heart failure, hypertension, age, diabetes mellitus, prior stroke or TIA or thromboembolism, vascular disease, age, sex category (CHA2DS2-VASc) scores. Statistical analysis identified patients with high CHA2DS2-VASc scores and defined the predictive value of individual parameters, or their combination, with regards to the outcomes of stroke and mortality. RESULTS: CHA2DS2-VASc scores identified 43.8% of the patients as low to intermediate risk (score 0-1) and 56.2% of the patients as high risk (score ≥2). Increasing CHA2DS2-VASc scores were not only accompanied by an increase in the incidence of stroke (Ptrend < .001) but also by an increase in the 3 to 5 years mortality (P = .005). Comparison of anticoagulation and anti-aggregation treatment between the 3 groups of AF did not show any significant statistical difference. Highly significant predictors of death were the CHA2DS2-VASc score (OR 1.71, 95% CI 1.10-2.67, P < .017) as well as other risk factors not included in the CHA2DS2-VASc score such as valvular heart disease (OR 5.04, 95% CI 1.10-23.10, P = .037), hyperlipidemia (OR 4.82, 95% CI 1.03-22.63, P = .046) and chronic renal failure (OR 14.21, 95% CI 2.41-83.91, P = .003). The type of AF type did not affect survival (P = .158) nor the incidence of stroke (P = .466). Patients with paroxysmal AF were linked to significantly lower frequencies of ischemic heart disease (P < .0001), vascular disease (P = .002), diabetes mellitus (P = .047), valvular heart disease (P = .03) and heart failure/left ventricular dysfunction (P = .015). CONCLUSION: The CHA2DS2-VASc score correctly predicted the patients at high-risk for 3 to 5 years mortality and confirmed its significant predictive value in the patients with AF.
No takes yet. Share an insight, caveat, or question.
Gažová et al. (2019) conducted a cohort in Atrial fibrillation (n=137). CHA2DS2-VASc score vs. Lower CHA2DS2-VASc score was evaluated on All-cause mortality (OR 1.71, 95% CI 1.10-2.67, p=<0.017). The CHA2DS2-VASc score significantly predicted 3- to 5-year all-cause mortality in patients with atrial fibrillation, with each 1-point increase raising the odds of death (OR 1.71).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: